Welcome to our dedicated page for MAIA Biotechnology SEC filings (Ticker: MAIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MAIA Biotechnology, Inc. filings document the regulatory record for a clinical-stage oncology company developing ateganosine for non-small cell lung cancer. Form 8-K reports cover THIO-101 clinical updates, oncology conference materials, shareholder communications on the development pipeline, FDA Fast Track disclosure, and forward-looking risk language tied to investigational drug development.
The company’s filings also document capital structure and governance matters, including an underwritten common stock offering conducted under an effective Form S-3 shelf registration, the related underwriting agreement and use-of-proceeds disclosure, executive compensation actions, and annual meeting proxy matters such as director elections and auditor ratification.
MAIA Biotechnology, Inc. (MAIA) director Ramiro Guerrero reported a series of open-market purchases of the company’s common stock. On August 26–28, 2026, he purchased a total of 133,790 shares in three transactions at per-share prices between $1.35 and $1.39, with no sales reported.
MAIA Biotechnology, Inc. (MAIA) director Ramiro Guerrero purchased common stock in an open-market or private transaction. On 2026-08-24, he bought 1,794 shares of MAIA common stock at a price of $1.33 per share, bringing his directly held position to 601,911 shares of common stock following the transaction.
MAIA Biotechnology, Inc. (MAIA) director Ramiro Guerrero reported purchasing common stock in an open market or private transaction. On 2026-08-20, he bought 11,899 shares at $1.37 per share, bringing his directly held position to 600,117 shares following the transaction. The filing indicates the Rule 10b5-1 checkbox was not selected.
MAIA Biotechnology, Inc. (MAIA) has filed a shelf registration on Form S-3 to offer, from time to time, up to $150,000,000 of common stock, preferred stock, debt securities, warrants, subscription rights and units. This is a primary, mixed-shelf program using a continuous or delayed offering format.
Under Rule 415(a)(6), the filing carries forward $94,010,093.10 of unsold securities from a 2023 shelf, with filing fees of $10,359.92 already paid. MAIA’s common stock trades on NYSE American under “MAIA,” closing at $1.39 on August 19, 2026, with 60,834,206 shares outstanding as of August 20, 2026.
MAIA is a clinical-stage biopharmaceutical company focused on targeted immunotherapies for cancer, led by ateganosine (THIO) for non-small cell lung cancer, now in Phase 2 (THIO-101) and a pivotal Phase 3 (THIO-104), with additional Phase 2 trials planned in HCC, CRC and SCLC. The company discloses ongoing losses, substantial additional funding needs, and substantial doubt about its ability to continue as a going concern, alongside extensive clinical, regulatory, intellectual-property and stock-price risks.
Solas Capital Management, LLC and Frederick Tucker Golden report beneficial ownership of 3,030,845 shares of MAIA Biotechnology, Inc. common stock. This represents 4.9% of the common stock outstanding, based on 60,800,758 shares outstanding as of May 11, 2026.
The shares are held by two private funds for the benefit of their investors, over which Solas acts as investment manager and sub-adviser, and Golden serves as Portfolio Manager. Both Solas and Golden report shared voting and dispositive power over all 3,030,845 shares and no sole voting or dispositive power. The funds themselves expressly disclaim beneficial ownership of the reported securities.
MAIA Biotechnology, Inc., a clinical-stage oncology company focused on telomere-targeting immunotherapy candidate ateganosine (THIO) for non-small cell lung cancer, reported higher operating spending and net losses for the three and six months ended June 30, 2026. For the six‑month period, research and development expenses were $9.16 million and general and administrative expenses were $6.10 million, driving a net loss of $14.31 million compared with $9.86 million a year earlier.
Cash strengthened significantly following March 2026 equity offerings, with cash of $27.60 million and working capital of $21.98 million at June 30, 2026, versus cash of $8.66 million at year‑end 2025. Net cash used in operating activities was $12.06 million for the six months, partially offset by $30.99 million of net cash from financing, mainly a confidentially marketed public offering. Total assets were $28.24 million and warrant liabilities measured at fair value were $1.31 million.
MAIA Biotechnology, Inc. director Steven M. Chaouki reported a compensation-related grant of stock options. He received options covering 26,982 shares of common stock at an exercise price of $1.44 per share, granted on June 30, 2026 under the company’s 2021 Equity Incentive Plan.
The options vest 100% on the grant date and are exercisable beginning that date, with an expiration date of June 30, 2036. Following this grant, Chaouki holds 26,982 stock options directly.
MAIA Biotechnology director Ramiro Guerrero received a grant of stock options, acquiring rights to 26,355 shares of common stock. The options have an exercise price of $1.44 per share, vest 100% on the grant date of June 30, 2026, and are exercisable immediately through June 30, 2036.
MAIA Biotechnology director Louie Ngar Yee received a grant of stock options on common shares. The award covers 32,630 options with an exercise price of $1.44 per share, granted under the company’s 2021 Equity Incentive Plan. The options vest 100% on the grant date and are immediately exercisable, expiring on June 30, 2036. Following this grant, Louie Ngar Yee holds 32,630 derivative securities directly.